Cytokine Blockade With Tocilizumab in Patients With Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis

Trial Profile

Cytokine Blockade With Tocilizumab in Patients With Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Cytokine release syndrome; Haemophagocytic lymphohistiocytosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Feb 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2021.
    • 05 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2021.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top